Daffodils may hold key to depression treatment in future

Plant compounds from a South African flower may in time be used to treat diseases originating in the brain – including depression, according to researchers. At the University of Copenhagen, a number of these substances have now been tested in a laboratory model of the blood-brain barrier. Pharmaceutical research Scientists from the University had previously documented that substances from the South African plant species Crinum and Cyrtanthus – akin to snowdrops and daffodils – have an effect on the mechanisms in the brain that are involved in depression. This research has now yielded further results, since a team based at the Faculty of Health and Medical Sciences has recently shown how several South African daffodils contain plant compounds whose characteristics enable them to negotiate the defensive blood-brain barrier that is a key challenge in all new drug development. “Several of our plant compounds can probably be smuggled past the brain’s effective barrier proteins. We examined various compounds for their influence on the transporter proteins in the brain,” Associate Professor Birger Brodin said. “This study was made in a genetically-modified cell model of the blood-brain barrier that contains high levels of the transporter P-glycoprotein. Our results are promising, and several of the chemical compounds studied should therefore be tested further, as candidates for long-term drug development. “The biggest challenge in medical treatment of diseases of the brain is that the drug cannot pass through the blood-brain barrier. The blood vessels of the brain are impenetrable for most compounds, one reason being the very active transporter proteins. You could say that the proteins pump the drugs out of the cells just as quickly as they are pumped in. So it is of great interest to find compounds that manage to ‘trick’ this line of defence,” Brodin said. However, it will take a long time before any possible new drug reaches our pharmacy shelves. “This is the first stage of a lengthy process, so it will take some time before we can determine which of the plant compounds can be used in further drug development,” Brodin said. Yet this does not curb his enthusiasm for the opportunities from the interdisciplinary cooperation with organic scientists from the Department of Drug Design and Pharmacology and the Natural History Museum of Denmark. “In my research group, we have had a long-term focus on the body’s barrier tissue – and in recent years particularly the transport of drug compounds across the blood-brain barrier,” Brodin emphasises. “More than 90 percent of all potential drugs fail the test by not making it through the barrier, or being pumped out as soon as they do get in. Studies of natural therapies are a valuable source of inspiration, giving us knowledge that can also be used in other contexts,” Brodin added. The results of the study have been published in the Journal of Pharmacy and Pharmacology.